Clinical Application of M6A in Cervical Cancer and Precancerous Lesions

N6-methyladenosine (m6A) is a key epigenetic modification in eukaryotic RNA. Studies in cervical cancer reveal that m6A levels and its modifying enzymes may serve as promising molecular markers for tumor progression monitoring and precision diagnosis. This paper aims to explore the relationship between Writer (methyltransferase), ERASERS (desmethyltransferase), Readers (recognition proteins) and cervical cancer cell molecules In m6A methylation modification, which are the regulators of m6A methylation modification, to provide new perspectives and strategies for the clinical diagnosis and treatment of pre-cancerous cervical lesions and cervical cancer. Modulating its expression in vivo may enhance cervical cancer cells’ radiotherapy sensitivity, potentially addressing chemotherapy resistance and improving therapeutic outcomes for advanced-stage cases.